abstract |
The present invention relates to a pharmaceutical composition comprising dimethyl fumarate (DMF). More specifically, the present invention provides an oral pharmaceutical composition for the treatment of hyperproliferative, inflammatory or autoimmune diseases by administering dimethyl fumarate at a low daily dose ranging from 410 mg ± 5% or 400 mg ± 5%. to, the pharmaceutical formulation thereof is an erosion matrix tablet. |